Blueprint Medicines is pulling back from one of its three areas of focus, dropping two non-small cell lung cancer (NSCLC) programs in response to early clinical data on the EGFR tyrosine kinase ...
Alexis Borisy, the founder of multiple biotech companies and self-dubbed “man of many hats,” may have to reduce two of his many duties. The Blueprint Medicines co-founder lost a majority vote for his ...
Finding an LSAT prep course that actually works shouldn’t feel like another test. With 176,000 students recently sitting for the Law School Admission Test, all competing for the same coveted law ...
Blueprint's Albers hands CEO baton to deal mastermind Haviland after steering 2 cancer drug launches
When Jeff Albers joined Blueprint Medicines in 2014, the private company was a clinical-stage biotech. Now, the helmsman is handing down the reins after steering the firm through an IPO and two drug ...
Blueprint Medicines is cutting funding to its clinical-stage CDK2 inhibitor even as the Ayvakit-maker pushes forward with similar preclinical breast cancer-focused therapies. The biopharma has three ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — Sanofi said Monday it plans to buy Blueprint Medicines in a deal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results